ACURX PHARMACEUTICALS INC (ACXP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.95-8.18%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ACXP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
ACXP — private placement
Dated 2026-04-16
Entry into a Material Definitive Agreement. On April 15, 2026, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Registered Offering”) (i) 816,068 shares (the “Shares”) of common stock, par value $0.001 per share, of th…
Why it matters: Acurx says the trial can advance only with suitable financing. A start would move its lead drug into a key test.
Supportive ifAcurx announces funding and a start date for the global Phase 3 ibezapolstat trial.
Worry ifAcurx reports it lacks funds to start the trial, or gives no start plan in its next update.
Why it matters: The offering brings in about $2.5 million before costs. Up to $4.6 million more depends on warrant exercise, which is not assured.
Watch forAcurx confirms the offering closed. It reports that warrant exercise brought in more cash.
Also watch forThe offering fails to close, or the warrants expire without exercise and no added cash is raised.
Why it matters: Acurx is loss-making and says its Phase 3 plan needs financing. Cash and trial updates can show if its plans can move ahead.
Watch forOn November 12, Acurx reports cash that supports its trial plans and gives a clear update on the pilot or Phase 3 timing.
Also watch forOn November 12, Acurx reports funding limits or a delay to the pilot or Phase 3 plan.
Why it matters: The warrants cover up to 1,650,170 shares. Exercise could add cash, but it also adds shares.
Worry ifAcurx reports exercise of a large share of the 1,650,170 warrants, increasing its share count.
Less concerning ifThe warrants expire with little or no exercise, and Acurx reports no new share issuance tied to them.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$172 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $958 loss on $10,000 · 9.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,574 loss on $10,000 · 85.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The pilot can show if ibezapolstat may help patients with repeated CDI. Favorable results could guide a larger trial.
Supportive ifAcurx reports good results from the open-label pilot in 20 patients. It shares plans for the Phase 3 trial.
Worry ifThe pilot results are poor, or Acurx does not move ahead with the planned Phase 3 trial after the results.